Company Overview and News

0
Repco Home Finance Limited - Updates

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535322 REPCOHOME

8
Will compulsory delivery impact F&O trading?

2018-06-29 thehindubusinessline
KS Badri Narayanan Be prepared to have enough money in your account if you want to trade in the 46 F&O stocks that have been moved to the compulsory delivery category by the NSE starting July. This follows the SEBI diktat in March to align the cash and derivative segments of the market, through physical settlement for all stock derivatives in a phased and calibrated manner. To start with, the NSE has initiated compulsory delivery in 46 stocks.
SRI 532939 SREINFRA GODREJIND 533096 UBL IDBI 532899 532712 532478 533106 JUSTDIAL GRANULES 535648 RCOM OIL 532482 KSCL DCBBANK RPOWER SIFLY 523756 ALNSE 500116 UBHOLDINGS 535322 SRIA UNBWY REPCOHOME 532772 ADANIPOWER 507458 500164 JSTQY

17
MFs offloaded shares in PowerGrid, InterGlobe Aviation in May

2018-06-20 thehindubusinessline
Suresh P Iyengar The mutual fund industry has offloaded 22 per cent of Power Grid Corporation shares worth ₹1,905 crore in May, as prospects of the company looked bleak with no major new power project being launched and a sharp decline in power generation.
RIFS 532617 HCTHY TTQQY TATACHEM 500390 PIDILITIND PDLTY 532281 HDFCBANK 500770 500331 INDIGO RELEY IBN RELFF JETAIRWAYS 535322 REPCOHOME 539448 RELINFRA ICICIBANK HDB 532174 500180 HCLTECH RIFA 534809 PCJEWELLER

0
Analysts see tough days ahead for housing finance companies

2018-06-08 thehindubusinessline
Our Bureau Share prices of housing finance companies will remain under pressure on margin concerns due to rising bond yields, say analysts.
GRUH GICHSGFIN DHFL 511072 LICHSGFIN GRHFY 535322 LHFLY 511676 500253 511288 REPCOHOME

0
Repco Home Finance Limited - Updates

2018-06-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535322 REPCOHOME

0
Creador-backed Vectus Industries said to plan IPO worth Rs500 crore

2018-04-17 livemint
Mumbai: Asia-focused private equity firm Creador-backed Vectus Industries Ltd, a maker of plastic storage tanks and pipes, is looking to go public and will soon file its draft prospectus for a Rs500 crore initial public offering (IPO), said two people aware of the development.
SOMANYCERA ASHIANA 523716 535322 534809 531548 PCJEWELLER REPCOHOME

0
Repco Home Finance Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535322 REPCOHOME

0
Repco Home Finance Limited - Trading Window

2018-03-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535322 REPCOHOME

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...